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Purpose: The aim of this analysis was to establish
the safety proﬁle and tolerability of empagliﬂozin in
patients with type 2 diabetes mellitus (T2DM) accord-
ing to pooled data from several clinical trials.
Methods: Pooled data were analyzed from patients
with T2DM treated with placebo (n ¼ 3695), empa-
gliﬂozin 10 mg (n ¼ 3806), or empagliﬂozin 25 mg
(n ¼ 4782) in 17 randomized, Phase I, II, and III
clinical trials plus 6 extension studies. Adverse events
(AEs) were assessed descriptively in patients who took
Z1 dose of the study drug. AE incidence rates per 100
patient-years were calculated to adjust for differences
in drug exposure across trials.
Findings: Total exposure was 3254, 3840, and
5649 patient-years in the placebo, empagliﬂozin 10
mg, and empagliﬂozin 25 mg groups, respectively. The
incidence of any AEs, AEs leading to treatment
discontinuation, severe AEs, and serious AEs was no
higher in patients treated with empagliﬂozin than with
placebo. Empagliﬂozin was not associated with an
increased risk of hypoglycemia versus placebo, except
in patients on background sulfonylurea and/or insulin.
The incidence of events consistent with urinary tract
infection was similar across treatment groups (9.4–
11.3/100 patient-years); 0.4%, 0.2%, and 0.3% of
patients in the placebo, empagliﬂozin 10 mg, and
empagliﬂozin 25 mg groups, respectively, had urinaryScan the QR Code with your phone to obtain
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GS2C65 to 64842. To scan QR Codes your
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June 2016tract infections that required or prolonged hospital-
ization. The incidence of events consistent with genital
infection was higher in patients treated with empagli-
ﬂozin (4.7 and 5.0/100 patient-years for empagliﬂozin
10 and 25 mg, respectively) than placebo (1.3/100
patient-years), but only 0.1%, 0.1%, and o0.1% in
the placebo, empagliﬂozin 10 mg, and empagliﬂozin
25 mg groups, respectively, had genital infections that
required or prolonged hospitalization. The incidence
of AEs consistent with volume depletion was similar
with placebo, empagliﬂozin 10 mg, and empagliﬂozin
25 mg (1.6, 1.5, and 1.3/100 patient-years, respec-
tively) and was higher with empagliﬂozin 25 mg than
placebo or empagliﬂozin 10 mg in patients aged 475
years (4.4 vs 2.3 and 2.5/100 patient-years, respec-
tively). The incidences of bone fractures, malignancies,
decreased renal function, hepatic injury, venous throm-
boembolic events, and diabetic ketoacidosis were low
and similar across the treatment groups.
Implications: In this predeﬁned analysis that was
based on 49000 patient-years’ exposure to empagli-
ﬂozin, empagliﬂozin 10 mg, and empagliﬂozin 25 mg
were well tolerated in patients with T2DM. (Clin
Ther. 2016;38:1299–1313) & 2016 The Authors.
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Clinical TherapeuticsINTRODUCTION
Empagliﬂozin is a potent and selective sodium glucose
cotransporter 2 (SGLT2) inhibitor1 used in the
treatment of type 2 diabetes mellitus (T2DM). By
reducing renal glucose reabsorption and so increasing
urinary glucose excretion, inhibiting SGLT2 leads to a
reduction in hyperglycemia in patients with T2DM.2
The mechanism of action of SGLT2 inhibitors is
independent of β-cell function; therefore, SGLT2 inhib-
itors are associated with a low risk of hypoglycemia.2
In Phase III trials, empagliﬂozin (10 and 25 mg)
used as monotherapy or as add-on to commonly used
antidiabetes drug regimens was associated with im-
provements in glycemic control and reductions in
weight and blood pressure versus placebo.3–8 In these
trials, empagliﬂozin was well tolerated with no in-
crease in conﬁrmed hypoglycemic events compared
with placebo, except as add-on to sulfonylurea or
ﬁxed-dose insulin.3–9 Adverse events (AEs) consistent
with urinary tract infection (UTI) were reported in
similar proportions of patients on empagliﬂozin and
placebo, but AEs consistent with genital infections
were reported in greater proportions of patients on
empagliﬂozin than placebo.3–9 In this study, we
present a comprehensive analysis of safety proﬁle data
pooled from 17 Phase I to III clinical trials plus 6
extension studies of empagliﬂozin in patients with
T2DM that was undertaken to characterize the safety
proﬁle and tolerability of empagliﬂozin. Analyzing
data pooled from several studies improves the preci-
sion of incidence estimates of AEs by enlarging the
sample size and can identify tolerability signals that
may be difﬁcult to detect in smaller studies.10 AE
incidence rates per 100 patient-years were calculated
to adjust for differences in drug exposure across trials.PATIENTS AND METHODS
Patient Population
For this analysis, data were pooled from all random-
ized controlled, blinded Phase I to III clinical trials of
empagliﬂozin in patients with T2DM. Pooled safety
proﬁle data were analyzed from patients with T2DM
treated with empagliﬂozin 10 or 25 mg in 16 random-
ized, Phase I to III clinical trials of 8 days’ to 104 weeks’
duration,3–9,11–19 plus 6 extension studies,20–25 plus an
interim analysis of data from a Phase III cardiovascular
outcomes trial.26 Patients who received active compara-
tors in these studies were not included in the analysis.1300Assessments
This pooled analysis of AEs was planned and
prespeciﬁed before the completion of the studies.
Assessment of safety proﬁle and tolerability was based
on AEs reported by the investigator (coded according
to the Medical Dictionary for Regulatory Activities
[MedDRA] version 16.1) and clinical laboratory tests.
Predeﬁned AEs of special interest included conﬁrmed
hypoglycemic AEs (plasma glucoser3.9 mmol/L and/
or requiring assistance); events consistent with UTI,
genital infection, and volume depletion; bone frac-
tures; malignancies; decreased renal function; and
hepatic injury. Events consistent with UTI, genital
infection, and volume depletion were assessed through
a search of 77, 89, and 8 MedDRA preferred terms,
respectively. Bone fractures were assessed through a
search of 60 MedDRA preferred terms. Malignancies,
decreased renal function, and hepatic injury were
assessed based on 2, 1, and 4 standardized MedDRA
queries, respectively. Diabetic ketoacidosis (DKA) and
venous thromboembolic events were assessed based on
searches of 3 and 5 MedDRA preferred terms, respec-
tively. AEs classiﬁed as severe, serious, or related to
the study drug were as reported by the investigator.
A severe AE was one judged to be incapacitating or
causing inability to work or to perform usual activ-
ities. A serious AE was one that resulted in death, was
immediately life-threatening, resulted in persistent or
marked disability/incapacity, required or prolonged
patient hospitalization, was a congenital anomaly/
birth defect, or was deemed serious for any other rea-
son that was based on appropriate medical judgment.
Data Analysis
Predeﬁned analyses of AEs were conducted using data
from patients who received Z1 dose of the study drug,
including patients who were re-randomized to receive
empagliﬂozin 10 or 25 mg in an extension study. AEs
were analyzed using descriptive statistics. AE frequencies
were calculated (n [%]), and exposure-adjusted incidence
rates were calculated per 100 patient-years ¼ 100  n/T,
where n was the number of subjects with the speciﬁed
event and T was the total patient-years. Patient-years
were deﬁned as the time from the ﬁrst dose to the onset
of the ﬁrst event (for patients with an event) or to the last
dose (for patients without an event).
The frequency of conﬁrmed hypoglycemic AEs
was analyzed by background antidiabetes medication
using descriptive statistics. Data were analyzedVolume 38 Number 6
S. Kohler et al.from patients randomized to receive empagliﬂozin
10 mg, empagliﬂozin 25 mg, or placebo once daily
for 24 weeks as monotherapy or as add-on to
metformin, add-on to metformin plus sulfonylurea,
or add-on to pioglitazone with or without metformin,
and from patients who received empagliﬂozin for 78
weeks as add-on to basal insulin or for 52 weeks as
add-on to daily multiple doses of insulin (MDIs).3–7,18
Laboratory values (except elevations in liver en-
zymes and bilirubin relative to the upper limit of
normal [ULN]) were analyzed in all patients who
receivedZ1 dose of the study drug, excluding patients
who switched to empagliﬂozin 10 or 25 mg in an
extension study. Elevations in liver enzymes and
bilirubin relative to ULN were analyzed in patients
who received Z1 dose of the study drug, including
patients who switched to empagliﬂozin 10 or 25 mg in
an extension study. Estimated glomerular ﬁltration
rate (eGFR; according to the Modiﬁcation of Diet in
Renal Disease equation) over time was analyzed in
patients with T2DM and chronic kidney disease
(CKD) who completed 52 weeks of treatment with
empagliﬂozin or placebo in a Phase III randomized
trial.15 In that trial, patients with CKD stage 2 (eGFR
Z60 and o90 mL/min/1.73 m2) were randomized to
receive empagliﬂozin 10 mg, empagliﬂozin 25 mg, or
placebo, and patients with CKD stage 3 (eGFR Z30
too60 mL/min/1.73 m2) or CKD stage 4 (eGFRZ15
to o30 mL/min/1.73 m2) were randomized to receive
empagliﬂozin 25 mg or placebo.15 Laboratory data
were analyzed using descriptive statistics.RESULTS
Patient Disposition, Baseline Characteristics, and
Exposure
In total, 3695 patients received placebo, 3806
received empagliﬂozin 10 mg, and 4782 received
empagliﬂozin 25 mg, including patients who were
re-randomized to receive empagliﬂozin 10 or 25 mg in
an extension study. Baseline demographic and clinical
characteristics were generally balanced between the
treatment groups with the exception of the number of
background antidiabetes medications (Table I; not
including patients who were re-randomized to receive
empagliﬂozin 10 or 25 mg in an extension study).
Total exposure was 3254, 3840, and 5649 patient-
years in the placebo, empagliﬂozin 10 mg, and
empagliﬂozin 25 mg groups, respectively.June 2016Summary of Adverse Events
The exposure-adjusted incidence of AEs, AEs con-
sidered drug-related by the investigator, and AEs
leading to treatment discontinuation are shown in
Table II. The incidence of severe AEs, serious AEs,
and fatal AEs was higher in the placebo group than in
the empagliﬂozin groups. The most common AEs
occurred at similar or higher incidence rates in the
placebo group than in the empagliﬂozin groups,
except for pollakiuria (Table II).
Hypoglycemia
The incidence of conﬁrmed hypoglycemic AEs de-
pended on background medication (Table III). When
used as monotherapy, add-on to metformin, or add-on
to pioglitazone with or without metformin, the per-
centage of patients with conﬁrmed hypoglycemic AEs
was low in all groups (Table III). When empagliﬂozin
was used as add-on to metformin plus sulfonylurea, the
incidence of conﬁrmed hypoglycemic AEs was higher
with empagliﬂozin than with placebo (Table III). No
conﬁrmed hypoglycemic AEs that required assistance
were reported in these studies (Table III).
When empagliﬂozin was used as add-on to ﬁxed-
dose basal insulin, the percentage of patients with
conﬁrmed hypoglycemic AEs was higher with empa-
gliﬂozin 25 mg than with placebo or empagliﬂozin
10 mg (Table III). Likewise, when empagliﬂozin was
used as add-on to ﬁxed-dose MDI, the percentage of
patients with conﬁrmed hypoglycemic AEs was higher
with empagliﬂozin 10 and 25 mg than with placebo.
When empagliﬂozin was added to ﬂexible doses of
basal insulin or MDI, the percentage of patients with
conﬁrmed hypoglycemic AEs was similar in all treat-
ment groups (Table III).
UTI
The incidence of events consistent with UTI was
similar in the placebo and empagliﬂozin groups (11.3,
10.4, and 9.4/100 patient-years in the placebo, empa-
gliﬂozin 10 mg, and empagliﬂozin 25 mg groups,
respectively). The incidence of events consistent with
UTI was much higher in female than male patients in
all treatment groups, but was similar between empa-
gliﬂozin and placebo in both male and female patients
(Table IV). Events consistent with UTI were mild or
moderate in 98% of patients who experienced them
and led to premature treatment discontinuation in a
small proportion of patients (0.2%, 0.4%, and 0.3%1301
Table I. Demographic and baseline characteristics.
Placebo
(n ¼ 3695)
Empagliﬂozin 10 mg
(n ¼ 3487)
Empagliﬂozin 25 mg
(n ¼ 4465)
Male, n (%) 2301 (62.3) 2208 (63.3) 2793 (62.6)
Age, years 60.3 (9.8) 60.1 (9.7) 59.6 (10.1)
Race, n (%)
White 2346 (63.5) 2250 (64.5) 2869 (64.3)
Asian 1164 (31.5) 1068 (30.6) 1404 (31.4)
Black/African-American 157 (4.2) 140 (4.0) 163 (3.7)
Other* 26 (0.7) 25 (0.7) 24 (0.5)
Missing 2 (0.1) 4 (0.1) 5 (0.1)
Time since diagnosis of T2DM, years, n (%)
r1 211 (5.7) 229 (6.6) 312 (7.0)
41 to 5 836 (22.6) 762 (21.9) 1115 (25.0)
45 2627 (71.1) 2472 (70.9) 3012 (67.5)
Missing 21 (0.6) 24 (0.7) 26 (0.6)
Background antidiabetes medications, n (%)
0 420 (11.4) 404 (11.6) 413 (9.2)
1 1162 (31.4) 1084 (31.1) 1887 (42.3)
2 1578 (42.7) 1487 (42.6) 1600 (35.8)
Other 535 (14.5) 512 (14.7) 565 (12.7)
Weight, kg 85.0 (19.7) 85.0 (20.0) 84.8 (19.8)
BMI, kg/m2 30.3 (5.5) 30.4 (5.7) 30.3 (5.6)
HbA1c, % 8.06 (0.83) 8.06 (0.84) 8.02 (0.83)
FPG, mmol/L 8.5 (2.3) 8.5 (2.3) 8.5 (2.2)
SBP, mm Hg 134.1 (16.8) 133.5 (16.2) 133.7 (16.4)
DBP, mm Hg 77.8 (9.7) 77.9 (9.6) 78.0 (9.4)
eGFR, mL/min/1.73m2 77.6 (22.6) 80.1 (21.5) 79.5 (22.3)
eGFR, mL/min/1.73m2, n (%)
Z90 1015 (27.5) 1019 (29.2) 1362 (30.5)
60 to o90 1908 (51.6) 1902 (54.5) 2310 (51.7)
30 to o60 718 (19.4) 554 (15.9) 732 (16.4)
o30 52 (1.4) 7 (0.2) 56 (1.3)
Missing 2 (0.1) 5 (0.1) 5 (0.1)
Data are mean (SD), unless otherwise indicated. Data from patients who receivedZ1 dose of the study drug, not including
patients who switched to empagliﬂozin 10 mg or 25 mg in an extension study.
BMI ¼ body mass index; eGFR ¼ estimated glomerular ﬁltration rate by Modiﬁcation of Diet in Renal Disease equation;
DBP ¼ diastolic blood pressure; FPG ¼ fasting plasma glucose; HbA1c ¼ glycosylated hemoglobin; SBP ¼ systolic blood
pressure; T2DM ¼ type 2 diabetes mellitus.
*American Indian/Alaska Native/Hawaiian/Paciﬁc Islander.
Clinical Therapeuticsin the placebo, empagliﬂozin 10 mg, and empa-
gliﬂozin 25 mg groups, respectively). The proportion
of patients with events consistent with UTI that re-
quired or prolonged hospitalization was similar in the1302placebo and empagliﬂozin groups (0.4%, 0.2%, and
0.3% in the placebo, empagliﬂozin 10 mg, and empa-
gliﬂozin 25 mg groups, respectively). The percentage
of patients with events consistent with UTI was similarVolume 38 Number 6
Table II. Summary of AEs.
Placebo (n ¼ 3695)
Empagliﬂozin 10 mg
(n ¼ 3806)
Empagliﬂozin 25 mg
(n ¼ 4782)
n (%)
Rate/100
patient-years n (%)
Rate/100
patient-years n (%)
Rate/100
patient-years
Z1 AE 2621 (70.9) 215.1 2686 (70.6) 176.3 3499 (73.2) 167.1
Z1 Investigator-reported
drug-related AE
636 (17.2) 22.6 845 (22.2) 26.7 1063 (22.2) 22.7
Z1 AE leading to
discontinuation
208 (5.6) 6.4 191 (5.0) 5.0 255 (5.3) 4.5
Z1 Severe AE* 324 (8.8) 10.4 258 (6.8) 6.9 373 (7.8) 6.8
Z1 Serious AE† 494 (13.4) 16.4 393 (10.3) 10.7 573 (12.0) 10.8
Deaths 29 (0.8) 0.9 19 (0.5) 0.5 26 (0.5) 0.5
AEs with frequency of Z2% in any group (by preferred term)
Hypoglycemia 602 (16.3) 21.1 597 (15.7) 17.6 677 (14.2) 13.2
Nasopharyngitis 290 (7.8) 9.4 345 (9.1) 9.6 420 (8.8) 7.9
Urinary tract infection 285 (7.7) 9.2 316 (8.3) 8.7 433 (9.1) 8.1
Hyperglycemia 426 (11.5) 14.4 211 (5.5) 5.7 304 (6.4) 5.6
Upper respiratory tract
infection
158 (4.3) 5.0 162 (4.3) 4.3 273 (5.7) 5.0
Back pain 135 (3.7) 4.2 136 (3.6) 3.6 221 (4.6) 4.0
Dizziness 112 (3.0) 3.5 141 (3.7) 3.8 196 (4.1) 3.6
Headache 116 (3.1) 3.6 117 (3.1) 3.1 195 (4.1) 3.5
Diarrhea 131 (3.5) 4.1 137 (3.6) 3.6 172 (3.6) 3.1
Inﬂuenza 101 (2.7) 3.1 83 (2.2) 2.2 160 (3.3) 2.9
Arthralgia 113 (3.1) 3.5 111 (2.9) 2.9 158 (3.3) 2.9
Hypertension 161 (4.4) 5.1 107 (2.8) 2.8 156 (3.3) 2.8
Bronchitis 109 (2.9) 3.4 102 (2.7) 2.7 124 (2.6) 2.2
Pollakiuria 39 (1.1) 1.2 90 (2.4) 2.4 121 (2.5) 2.2
Dyslipidemia 94 (2.5) 2.9 95 (2.5) 2.5 119 (2.5) 2.1
Cough 116 (3.1) 3.6 82 (2.2) 2.2 117 (2.4) 2.1
Pain in extremity 80 (2.2) 2.5 85 (2.2) 2.2 107 (2.2) 1.9
Edema peripheral 74 (2.0) 2.3 28 (0.7) 0.7 40 (0.8) 0.7
Data are n (%) in patients who receivedZ1 dose of the study drug, including patients who switched to empagliﬂozin 10 mg
or 25 mg in an extension study.
AE ¼ adverse event.
*AE that is incapacitating or causing inability to work or to perform usual activities.
†AE that results in death, is immediately life-threatening, results in persistent or signiﬁcant disability/incapacity, requires or
prolongs patient hospitalization, is a congenital anomaly/birth defect, or is deemed serious for any other reason based on
appropriate medical judgment.
S. Kohler et al.between empagliﬂozin and placebo in patients with
or without a history of chronic or recurrent UTI.
However, events consistent with UTI were reported by
a higher proportion of patients with a historyJune 2016of chronic or recurrent UTI (27.8%, 25.7%, and
29.9% in the placebo, empagliﬂozin 10 mg, and
empagliﬂozin 25 mg groups, respectively) than in
patients without such a history (8.8%, 9.1%, and1303
Table III. Confirmed hypoglycemic adverse events by study.
Placebo
Empagliﬂozin
10 mg
Empagliﬂozin
25 mg
Monotherapy (24 weeks; Roden 2013), n 229 224 223
Conﬁrmed hypoglycemic adverse events* 1 (0.4) 1 (0.4) 1 (0.4)
Requiring assistance 0 0 0
Add-on to metformin (24 weeks; Haering 2014), n 206 217 214
Conﬁrmed hypoglycemic adverse events* 1 (0.5) 4 (1.8) 3 (1.4)
Requiring assistance 0 0 0
Add-on to metformin þ sulfonylurea (24 weeks; Haering 2013), n 225 224 217
Conﬁrmed hypoglycemic adverse events* 19 (8.4) 36 (16.1) 25 (11.5)
Requiring assistance 0 0 0
Add-on to pioglitazone  metformin (24 weeks; Kovacs 2014), n 165 165 168
Conﬁrmed hypoglycemic adverse events* 3 (1.8) 2 (1.2) 4 (2.4)
Requiring assistance 0 0 0
Add-on to basal insulin (18 weeks/78 weeks†; Rosenstock 2015), n 170 169 155
18 weeks
Conﬁrmed hypoglycemic adverse events* 35 (20.6) 33 (19.5) 44 (28.4)
Requiring assistance 0 0 1 (0.6)
78 weeks
Conﬁrmed hypoglycemic adverse events* 60 (35.3) 61 (36.1) 56 (36.1)
Requiring assistance 0 0 2 (1.3)
Add-on to MDI  metformin (18 weeks/52 weeks‡;
Rosenstock 2014), n
188 186 189
18 weeks
Conﬁrmed hypoglycemic adverse events* 70 (37.2) 74 (39.8) 78 (41.3)
Requiring assistance 1 (0.5) 1 (0.5) 1 (0.5)
52 weeks
Conﬁrmed hypoglycemic adverse events* 109 (58.0) 95 (51.1) 109 (57.7)
Requiring assistance 3 (1.6) 3 (1.6) 1 (0.5)
Data are n (%) in patients who received Z1 dose of the study drug.
MDI ¼ multiple dose of insulin.
*Plasma glucose r3.9 mmol/L and/or requiring assistance.
†The dose of insulin was to remain stable in weeks 1 to 18 then be adjusted during weeks 19 to 78 to meet glucose target.
‡The dose of insulin was to be stable in weeks 1 to 18, adjusted to meet glucose targets in weeks 19 to 40, then stable in
weeks 41 to 52.
Clinical Therapeutics9.3%, respectively). Acute pyelonephritis was
reported in 0.1% of patients on placebo and
o0.1% in each empagliﬂozin group. Urosepsis was
reported in 0.1%, 0.1%, and o0.1% of patients in
the placebo, empagliﬂozin 10 mg, and empagliﬂozin
25 mg groups, respectively. All patients with urosepsis
recovered.1304Genital Infection
The incidence of events consistent with genital
infection was higher in patients treated with empagli-
ﬂozin than with placebo (1.3, 4.7, and 5.0/100
patient-years in the placebo, empagliﬂozin 10 mg,
and empagliﬂozin 25 mg groups, respectively). The
incidence of events consistent with genital infectionVolume 38 Number 6
Table IV. AEs of special interest.
AE event
Placebo (N ¼ 3695)
Empagliﬂozin 10 mg
(N ¼ 3806)
Empagliﬂozin 25 mg
(N ¼ 4782)
n (%) or n/N (%)
Rate/100
patient-
years n (%) or n/N (%)
Rate/100
patient-
years n (%) or n/N (%)
Rate/100
patient-
years
AEs consistent with urinary tract infection* 344 (9.3) 11.3 374 (9.8) 10.4 497 (10.4) 9.4
Sex
Male 75/2301 (3.3) 3.8 93/2417 (3.8) 3.9 137/2987 (4.6) 4.0
Female 269/1394 (19.3) 25.3 281/1389 (20.2) 22.8 360/1795 (20.1) 19.2
AEs consistent with genital infection† 41 (1.1) 1.3 177 (4.7) 4.7 268 (5.6) 5.0
Sex
Male 18/2301 (0.8) 0.9 83/2417 (3.4) 3.5 112/2987 (3.7) 3.3
Female 23/1394 (1.6) 1.8 94/1389 (6.8) 6.8 156/1795 (8.7) 7.7
AEs consistent with volume depletion‡ 51 (1.4) 1.6 57 (1.5) 1.5 74 (1.5) 1.3
Age
o50 years 4/495 (0.8) 0.9 2/560 (0.4) 0.3 9/769 (1.2) 0.9
50 to o65 years 21/1953 (1.1) 1.2 22/2014 (1.1) 1.1 25/2483 (1.0) 0.8
65 to o75 years 21/1011 (2.1) 2.5 28/1012 (2.8) 2.9 28/1251 (2.2) 2.1
475 years 5/236 (2.1) 2.3 5/220 (2.3) 2.5 12/279 (4.3) 4.4
Diuretic use at baseline
Yes 27/1190 (2.3) 2.5 30/1167 (2.6) 2.6 41/1439 (2.8) 2.6
No 24/2505 (1.0) 1.1 27/2639 (1.0) 1.0 33/3343 (1.0) 0.8
Loop diuretic use at baseline
Yes 10/352 (2.8) 3.2 14/279 (5.0) 5.6 12/376 (3.2) 3.4
No 41/3343 (1.2) 1.4 43/3527 (1.2) 1.2 62/4406 (1.4) 1.2
Bone fractures§ 67 (1.8) 2.1 66 (1.7) 1.7 63 (1.3) 1.1
eGFR Z90 mL/min/1.73m2 7/1015 (0.7) 0.8 19/1143 (1.7) 1.6 27/1474 (1.8) 1.5
eGFR 60 to o90 mL/min/1.73m2 36/1908 (1.9) 2.2 31/2094 (1.5) 1.5 23/2500 (0.9) 0.8
eGFR 45 to o60 mL/min/1.73m2 18/479 (3.8) 4.1 14/419 (3.3) 3.6 8/521 (1.5) 1.6
eGFR 30 to o45 mL/min/1.73m2 6/239 (2.5) 2.7 2/138 (1.4) 1.7 5/225 (2.2) 2.4
eGFR o30 mL/min/1.73m2 0/52 0 0/7 0 0/56 0
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Table IV. (continued).
AE event
Placebo (N ¼ 3695)
Empagliﬂozin 10 mg
(N ¼ 3806)
Empagliﬂozin 25 mg
(N ¼ 4782)
n (%) or n/N (%)
Rate/100
patient-
years n (%) or n/N (%)
Rate/100
patient-
years n (%) or n/N (%)
Rate/100
patient-
years
Malignancies¶ 36 (1.0) 1.1 46 (1.2) 1.2 67 (1.4) 1.2
With onset Z6 months from start of treatment/
patients with exposure Z6 months
22/2446 (0.9) 1.3 30/2860 (1.0) 1.4 39/3751 (1.0) 1.1
Bladder cancer║ 0 NC 2 (0.1) NC 0 NC
Renal cancer# 2 (0.1) NC 0 NC 1 (o0.1) NC
Breast cancer** 2 (0.1) NC 1 (o0.1) NC 1 (o0.1) NC
Melanoma†† 1 (o0.1) NC 2 (0.1) NC 4 (0.1) NC
Lung cancer‡‡ 1 (o0.1) NC 2 (0.1) NC 4 (0.1) NC
AEs consistent with decreased renal function§§ 36 (1.0) 1.1 46 (1.2) 1.2 64 (1.3) 1.1
Hepatic injury¶¶ 66 (1.8) 2.0 52 (1.4) 1.4 82 (1.7) 1.5
Diabetic ketoacidosis║║ 5 (0.1) 0.1 2 (0.1) 0.1 1 (o0.1) o0.1
Venous thromboembolic events## 9 (0.2) 0.3 3 (0.1) 0.1 8 (0.2) 0.1
Data from patients who receivedZ1 dose of the study drug, including patients who switched to empagliﬂozin 10 mg or 25 mg in an extension study, unless otherwise indicated.
AE ¼ adverse event; eGFR ¼ estimated glomerular ﬁltration rate by Modiﬁcation of Diet in Renal Disease equation; MedDRA ¼ Medical Dictionary for Regulatory Activities;
NC ¼ not calculated.
*Based on 77 MedDRA preferred terms; 23 were reported, of which urinary tract infection, cystitis, and asymptomatic bacteriuria were the most frequent.
†Based on 89 MedDRA preferred terms; 29 were reported, of which vulvovaginal mycotic infection, balanitis, and vulvovaginal candidiasis were the most frequent.
‡Based on 8 MedDRA preferred terms; 6 were reported, of which hypotension, syncope, and orthostatic hypotension were the most frequent.
§Based on 60 MedDRA preferred terms; 31 were reported, of which traumatic fracture, foot fracture, and tooth fracture were the most frequent.
¶Based on 2 standardized MedDRA queries.
║Bladder cancer/bladder neoplasm.
#Renal cancer/renal cell carcinoma.
**Breast cancer/invasive ductal breast cancer.
††Malignant melanoma/malignant melanoma in situ.
‡‡Lung neoplasm malignant/lung cancer metastatic/non–small cell lung cancer/squamous cell carcinoma of lung.
§§Based on 1 standardized MedDRA query.
¶¶Based on 4 standardized MedDRA queries.
║║Based on 3 MedDRA preferred terms.
##Based on 5 MedDRA preferred terms.
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S. Kohler et al.was higher in female than male patients in all treat-
ment groups, and was higher with empagliﬂozin
than with placebo in male and female patients
(Table IV). Events consistent with genital infection
were mild or moderate in 99% of patients who
experienced them and led to premature treatment
discontinuation in a small proportion of patients
(o0.1%, 0.4%, and 0.5% in the placebo, empagli-
ﬂozin 10 mg, and empagliﬂozin 25 mg groups,
respectively). The proportion of patients with events
consistent with genital infection that required or
prolonged hospitalization was similar in the placebo
and empagliﬂozin groups (0.1%, 0.1%, and o0.1%
in the placebo, empagliﬂozin 10 mg, and empagli-
ﬂozin 25 mg groups, respectively). The percentage of
patients with events consistent with genital infection
was greater with empagliﬂozin than with placebo in
patients with a history of chronic or recurrent genital
infection (7.8%, 17.1%, and 20.5% in the placebo,
empagliﬂozin 10 mg, and empagliﬂozin 25 mg groups,
respectively) and in patients without such a history
(1.0%, 4.4%, and 5.5%, respectively).
Volume Depletion
The incidence of events consistent with volume deple-
tion was similar with empagliﬂozin and placebo (1.6, 1.5,
and 1.3/100 patient-years for the placebo, empagliﬂozin
10 mg, and empagliﬂozin 25 mg groups, respectively).
The incidence of these events was similar between
empagliﬂozin and placebo within age subgroups, except
for a higher incidence with empagliﬂozin 25 mg than
placebo or empagliﬂozin 10 mg in patients aged 475
years (4.4 versus 2.3 and 2.5/100 patient-years, respec-
tively). The incidence of events consistent with volume
depletion was similar between empagliﬂozin and placebo
regardless of use of diuretics at baseline, but in patients
who received loop diuretics at baseline, the incidence was
3.2, 5.6, and 3.4/100 patient-years with placebo, empagli-
ﬂozin 10 mg, and empagliﬂozin 25 mg, respectively.
Malignancies
The incidence of malignancies was similar in the
placebo (1.1/100 patient-years) and empagliﬂozin
groups (1.2/100 patient-years in both dose groups).
The incidence of malignancies with an onset 46
months from the start of treatment was similar in
the placebo and empagliﬂozin groups (1.3, 1.4, and
1.1/100 patient-years in the placebo, empagliﬂozin
10 mg, and empagliﬂozin 25 mg groups, respectively),June 2016with no apparent difference in the incidence of any
speciﬁc type of cancer between empagliﬂozin and
placebo (Table IV).Renal Laboratory Parameters and Renal AEs
Small increases were found in serum creatinine and
small decreases in eGFR in all 3 treatment groups,
with larger changes in the empagliﬂozin groups than
in the placebo group (Table V). Of note, in a
dedicated renal safety proﬁle study in patients with
T2DM and stage 2 to 4 CKD, decreases in eGFR
observed with empagliﬂozin over 52 weeks of
treatment returned to baseline values after a 3-week
post-treatment follow-up period (Figure).15 The
incidence of events consistent with decreased renal
function was similar in the placebo and empagliﬂozin
groups (1.1, 1.2, and 1.1/100 patient-years for the
placebo, empagliﬂozin 10 mg, and empagliﬂozin
25 mg groups, respectively).
Serum uric acid decreased in patients treated with
empagliﬂozin versus a small increase in the placebo
group (Table V). No increase was found in the
incidence of nephrolithiasis with empagliﬂozin versus
placebo (1.0, 0.5, and 0.5/100 patient-years in the
placebo, empagliﬂozin 10 mg, and empagliﬂozin
25 mg groups, respectively) or in the incidence of
gout with empagliﬂozin versus placebo (0.7, 0.5, and
0.4/100 patient-years in the placebo, empagliﬂozin 10
mg, and empagliﬂozin 25 mg groups, respectively).Hepatic Laboratory Parameters and AEs
No clinically relevant changes were found in alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase, or total bilirubin in any
treatment group (Table V). Elevations in liver enzymes
to Z3 times ULN were rare in all treatment groups
(Table VI). Greater proportions of patients had ALT
and/or AST Z5 times ULN and ALT and/or AST Z3
times ULN with bilirubin Z2 times ULN with
empagliﬂozin than with placebo (Table VI), but these
elevations were explained by viral infections or the
effects of concomitant medication. No cases met Hy’s
Law criteria. The incidence of events consistent with
hepatic injury was similar in the placebo and
empagliﬂozin groups (2.0, 1.4, and 1.5/100 patient-
years in the placebo, empagliﬂozin 10 mg, and empa-
gliﬂozin 25 mg groups, respectively).1307
Table V. Laboratory results.
Placebo Empagliﬂozin 10 mg Empagliﬂozin 25 mg
Baseline
Change
from
baseline* Baseline
Change
from
baseline* Baseline
Change
from
baseline*
Hematocrit, % 41.5 (5.4) –0.1 (3.6) 41.7 (5.3) 3.4 (4.1) 41.7 (5.3) 3.6 (4.2)
Hemoglobin, g/L 136 (15) –1 (9) 137 (14) 7 (10) 137 (14) 7 (10)
Uric acid, mmol/L 330.1 (138.6) 3.0 (86.8) 315.8 (127.9) –32.7 (92.8) 323.6 (131.5) –36.3 (95.2)
Serum creatinine, mmol/L 89.3 (24.8) 0.9 (13.3) 85.7 (17.7) 1.8 (10.6) 86.6 (23.0) 1.8 (13.3)
eGFR, mL/min/1.73m2 77.6 (22.6) –0.5 (11.4) 80.1 (21.5) –0.9 (11.7) 79.5 (22.3) –1.0 (12.1)
Aspartate aminotransferase, U/L 15 (13) 0 (12) 15 (11) –1 (14) 15 (12) –1 (33)
Alanine aminotransferase, U/L 21 (15) –1 (13) 20 (14) –3 (16) 21 (15) –3 (31)
Alkaline phosphatase, U/L 67 (32) 1 (34) 67 (32) 0 (17) 68 (33) 1 (20)
Total bilirubin, mmol/L 9.0 (3.3) –0.1 (2.3) 8.9 (3.1) 0.1 (2.5) 9.0 (3.1) 0.1 (4.8)
25-Hydroxy vitamin D, nmol/L 75.4 (35.7) 2.6 (40.0) 77.9 (33.7) 3.1 (34.8) 84.4 (41.2) 4.1 (38.1)
Urinary N-telopeptide (nmol/L)/
creatinine (mmol/L) ratio
41 (24) –2 (17) 40 (20) 3 (19) 34 (23) 4 (24)
Parathyroid hormone, ng/L 42.3 (19.3) –3.0 (15.7) 42.2 (18.1) 0.4 (15.0) 36.9 (35.5) –1.2 (31.0)
Electrolytes
Sodium, mmol/L 141 (2) 0 (2) 141 (2) 0 (2) 141 (2) 0 (2)
Potassium, mmol/L 4.2 (0.3) 0.0 (0.3) 4.2 (0.3) 0.0 (0.3) 4.2 (0.3) 0.0 (0.3)
Calcium, mmol/L 2.5 (0.1) 0.0 (0.1) 2.4 (0.1) 0.0 (0.1) 2.5 (0.1) 0.0 (0.1)
Magnesium, mmol/L 0.9 (0.1) 0.0 (0.1) 0.9 (0.1) 0.1 (0.1) 0.9 (0.1) 0.1 (0.1)
Phosphate, mmol/L 1.2 (0.1) 0.0 (0.1) 1.2 (0.1) 0.0 (0.1) 1.2 (0.1) 0.0 (0.1)
Total cholesterol, mmol/L 4.5 (1.2) 0.1 (0.8) 4.5 (1.2) 0.1 (0.9) 4.5 (1.1) 0.2 (0.9)
HDL-cholesterol, mmol/L 1.2 (0.3) 0.0 (0.2) 1.2 (0.3) 0.0 (0.2) 1.2 (0.3) 0.1 (0.2)
LDL-cholesterol, mmol/L 2.4 (1.0) 0.1 (0.7) 2.4 (1.0) 0.1 (0.8) 2.4 (0.9) 0.1 (0.7)
LDL-cholesterol/HDL-cholesterol ratio 2.1 (1.0) 0.1 (0.8) 2.1 (0.9) 0.0 (0.7) 2.1 (0.9) 0.0 (0.7)
Triglycerides, mmol/L 1.9 (1.4) 0.1 (1.3) 1.9 (1.7) 0.0 (1.6) 1.9 (1.5) 0.0 (1.2)
Apolipoprotein A-I, g/L 1.26 (0.06) 0.00 (0.04) 1.26 (0.06) 0.01 (0.04) 1.26 (0.06) 0.01 (0.05)
Apolipoprotein B, g/L 0.95 (0.53) 0.07 (0.38) 0.95 (0.53) 0.08 (0.41) 0.96 (0.51) 0.11 (0.38)
Data are mean (SD) in patients who received Z1 dose of the study drug, excluding patients who switched to empagliﬂozin
10 mg or 25 mg in an extension study. Data are normalized to a standard reference range, except for eGFR and lipids.
eGFR ¼ estimated glomerular ﬁltration rate by Modiﬁcation of Diet in Renal Disease equation;
HDL = high-density lipoprotein; LDL = low-density lipoprotein
*Changes from baseline at last value on treatment.
Clinical TherapeuticsHematocrit and Venous Thromboembolic Events
Hemoglobin and hematocrit increased in patients
treated with empagliﬂozin, with almost no change in
the placebo group (Table V). The incidence of venous
thromboembolic events was low in all groups (0.3,
0.1, and 0.1/100 patient-years in the placebo, empa-
gliﬂozin 10 mg, and empagliﬂozin 25 mg groups,
respectively).1308Electrolytes, Parathyroid Hormone, and Bone Fractures
No meaningful changes were found in serum
electrolytes (sodium, potassium, calcium, magnesium,
and phosphate), alkaline phosphatase, 25-hydroxy
vitamin D, urinary N-telopeptide (NTx)/creatinine
ratio, or parathyroid hormone in any treatment group
(Table V). The incidence of bone fractures was similar
in the placebo and empagliﬂozin groups (2.1, 1.7, andVolume 38 Number 6
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Figure. Estimated glomerular filtration rate (eGFR) over time, including after treatment follow-up period
(dotted lines) in patients with chronic kidney disease (CKD). Empa ¼ empagliflozin.
S. Kohler et al.1.1/100 patient-years for the placebo, empagliﬂozin 10
mg, and empagliﬂozin 25 mg groups, respectively). No
imbalance was found in the incidence of bone fractures
between empagliﬂozin and placebo within renal func-
tion (eGFR) subgroups (Table IV).Table VI. Elevations in liver enzymes and bilirubin.
Placebo
(n ¼ 3695)
ALT and/or AST Z3 times ULN 37 (1.0)
ALT and/or AST Z5 times ULN 3 (0.1)
ALT and/or AST Z3 times ULN
with bilirubin Z2 times ULN
0
Data are n (%) in patients who receivedZ1 dose of the study dr
or 25 mg in an extension study.
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransfe
June 2016Lipid Parameters
Increases in LDL-cholesterol and total cholesterol
were observed in all treatment groups, including the
placebo group. A small increase from baseline was
found in HDL-cholesterol with empagliﬂozin 25 mg.Empagliﬂozin 10 mg
(n ¼ 3806)
Empagliﬂozin 25 mg
(n ¼ 4782)
21 (0.6) 31 (0.6)
7 (0.2) 12 (0.3)
2 (0.1) 3 (0.1)
ug, including patients who switched to empagliﬂozin 10 mg
rase; ULN ¼ upper limit of normal.
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Table VII. Urine ketone amounts: worst recorded measurement on treatment.
Placebo (n ¼ 3275) Empagliﬂozin 10 mg (n ¼ 3090) Empagliﬂozin 25 mg (n ¼ 3998)
Negative 2870 (87.6) 2518 (81.5) 3249 (81.3)
Trace 293 (8.9) 337 (10.9) 416 (10.4)
1þ 96 (2.9) 174 (5.6) 249 (6.2)
Z2þ 16 (0.5) 61 (2.0) 84 (2.1)
Data are n (%) in patients who receivedZ1 dose of the study drug, including patients who switched to empagliﬂozin 10 mg
or 25 mg in an extension study.
Clinical TherapeuticsNo changes in LDL-cholesterol/HDL-cholesterol ratio
or triglycerides were observed with empagliﬂozin 10
mg or 25 mg (Table V). Almost no change in
apolipoprotein A-I was found in any treatment group
(Table V). Increases in apolipoprotein B were similar
between placebo and empagliﬂozin 10 mg, but were
slightly greater with empagliﬂozin 25 mg (Table V).DKA
Greater proportions of patients on empagliﬂozin
had urine ketone amounts Z1þ compared with
placebo (Table VII), but the proportions of patients
with DKA was similar between groups. DKA
was reported in 5 (0.1%), 2 (0.1%), and 1 (o0.1%)
patients in the placebo, empagliﬂozin 10 mg, and
empagliﬂozin 25 mg groups, respectively. The
incidence of DKA was 0.12, 0.05, and 0.02/100
patient-years in the placebo, empagliﬂozin 10 mg,
and empagliﬂozin 25 mg groups, respectively. DKA
was reported in 2 male patients and 1 female patient
treated with empagliﬂozin. Two of the patients were
on insulin. One patient had a UTI as a precipitating
factor. One patient was diagnosed with DKA on the
basis of positive urine ketone bodies without acidosis.
All patients recovered, and 2 patients continued treat-
ment with empagliﬂozin.DISCUSSION
This comprehensive analysis of the safety proﬁle data
pooled from Phase I to III clinical trials of empagli-
ﬂozin which involved 413,000 patients with T2DM
was undertaken to establish the safety proﬁle and
tolerability of empagliﬂozin. The total incidences of
AEs, severe AEs, serious AEs, and AEs leading to drug1310discontinuation were not increased in patients treated
with empagliﬂozin compared with placebo.
Empagliﬂozin was not associated with an increased
risk of hypoglycemia compared with placebo, except
when used in combination with sulfonylurea and/or
basal insulin. Empagliﬂozin monotherapy would not
be expected to be associated with an increased risk of
hypoglycemia on the basis of its mode of action,
which is independent of the action of insulin.2
However, sulfonylureas are associated with an
increased risk of hypoglycemia, and an increase in
hypoglycemia was reported when other antidiabetes
medications, including other SGLT2 inhibitors,27,28
glucagon-like peptide-1 agonists,29 and dipeptidyl
peptidase-4 inhibitors,30 are used in combination
with a sulfonylurea. Consideration should be given
to reducing the dose of sulfonylurea to reduce the risk
of hypoglycemia when a sulfonylurea is used with
empagliﬂozin.31 A reduction in insulin dose should be
considered when insulin is used in combination with
empagliﬂozin to reduce the risk of hypoglycemia.31
SGLT2 inhibitors are associated with osmotic diu-
resis because of increased loss of glucose in the urine.2
The potential for volume depletion in vulnerable
patients such as the elderly, patients with renal
impairment, patients with low systolic blood pressure,
and patients receiving diuretics is acknowledged in
the prescribing information for empagliﬂozin.31 In
this large data set, the overall incidence of events
consistent with volume depletion was similar with
empagliﬂozin and placebo, but a higher incidence of
events consistent with volume depletion was observed
in patients aged Z75 years and in patients who
receiving loop diuretics at baseline. AEs of pollakiuria
were reported more frequently in patients treated with
empagliﬂozin than with placebo.Volume 38 Number 6
S. Kohler et al.The incidence of events consistent with genital
infection was higher in patients treated with empagli-
ﬂozin than with placebo, but such events rarely re-
quired or prolonged hospitalization. An increased risk
of genital infections, particularly in female patients, has
also been observed with other SGLT2 inhibitors.32,33 In
this pooled analysis, the incidence of events consistent
with UTI was similar in patients treated with empagli-
ﬂozin and placebo, but an increased risk of events
consistent with UTI, particularly in female patients, has
been observed in some trials and is acknowledged in the
product label.31 Few events consistent with UTI
required or prolonged hospitalization.
Empagliﬂozin increases afferent arteriolar glomeru-
lar resistance without an alteration in efferent arteriolar
resistance, leading to a reduction in glomerular hyper-
ﬁltration.34,35 Thus, the reductions in eGFR observed
with empagliﬂozin are likely to be hemodynamic in
nature, and Phase III studies have found that they are
reversible after treatment discontinuation.7,15,17,18 Of
note, in this large data set, there was no increase in the
incidence of events consistent with decreased renal
function with empagliﬂozin compared with placebo.
Imbalances in bladder and breast cancer were ob-
served with another SGLT2 inhibitor, but analyses were
based on short exposure times and small numbers.36 In
this pooled data set, the incidence of malignancies was
similar between placebo and empagliﬂozin. Importantly,
the incidence was similar for malignancies with an onset
46 months after the start of treatment, before which a
causal link is unlikely, and no differences were found in
the incidence of any speciﬁc type of cancer between
empagliﬂozin and placebo.
SGLT2 inhibition results in a negative energy balance
because of loss of glucose in the urine, leading to
a decreased insulin-to-glucagon ratio.37 As a conse-
quence, SGLT2 inhibition may lead to an increase in
fasting amounts of ketone bodies in patients with
T2DM.38 In this large data set, although increased
urine ketone amounts were reported in a greater
proportion of patients on empagliﬂozin than on
placebo, the incidence of DKA was low and no higher
with empagliﬂozin than with placebo.
Increases in HDL-cholesterol and LDL-cholesterol
were observed in some trials of SGLT2 inhibitors,39
which may be partly due to hemoconcentration
effects.40 However, in this pooled analysis, changes
in serum lipids were similar in the empagliﬂozin and
placebo groups. Changes in LDL-cholesterol andJune 2016apolipoprotein B were small and proportional and
suggested that LDL particle size did not change.
It was hypothesized that changes in renal sodium and
glucose reabsorption by SGLT2 inhibition may affect
bone metabolism through modulation of the renal
reabsorption of calcium and phosphate,41 and an
increased risk of bone fracture is listed as a side effect
of another SGLT2 inhibitor.42 However, in this pooled
analysis, no increase in bone fractures was found in
patients treated with empagliﬂozin compared with
placebo, including patients with stage 2 to 4 CKD.
The glucose transporter (GLUT) 9 in the proximal
tubule transports uric acid and glucose.43 SGLT2
inhibition is believed to lead to an increased efﬂux of
uric acid into the urine as a result of an increased glucose
concentration in the proximal tubule, which stimulates
GLUT9-mediated uric acid excretion and inhibits
GLUT9-mediated uric acid reabsorption.44 Consistent
with this and the results of individual studies, decreases
in serum uric acid were observed in patients treated with
empagliﬂozin in this pooled analysis, and no increase
was found in the incidence of nephrolithiasis with
empagliﬂozin compared with placebo.
Strengths of this analysis include the large sample
size and that it was prespeciﬁed. Limitations of this
pooled analysis are that the studies included were of
varying durations and that differences between groups
were not compared with modeled analyses. In addition,
it is possible that rare AEs may not be captured in the
exposure time of this analysis; therefore, postmarketing
surveillance will be important to identify rare AEs.CONCLUSIONS
In conclusion, in this predeﬁned analysis of pooled
data that was based on 49000 patient-years’ expo-
sure to empagliﬂozin, empagliﬂozin 10 and 25 mg
were well tolerated in patients with T2DM. Compared
with placebo, the reported frequency of events con-
sistent with UTI, bone fractures, malignancies, de-
creased renal function, or DKA was not increased
with empagliﬂozin 10 or 25 mg in the presented data.
Empagliﬂozin was not associated with a higher rate of
hypoglycemic events compared with placebo, except
in patients on background sulfonylurea and/or insulin.
The incidence of events consistent with genital infec-
tion was higher with empagliﬂozin than with placebo.
The incidence of AEs consistent with volume depletion
was similar between empagliﬂozin and placebo but1311
Clinical Therapeuticswas higher with empagliﬂozin 25 mg in patients aged
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